Aptevo unveils preclinical bispecific APVO442 for prostate cancer; targets $14B market

Aptevo Therapeutics Inc.

APVO442 is a PSMA x CD3 bispecific antibody designed to treat prostate cancer.
First molecule developed using Aptevo's ADAPTIR-FLEX platform.
Prostate cancer market valued at ~$14B, expected to grow to $24B+ over ten years.
Preclinical studies show tumor localization and reduced binding to circulating immune cells.
Aims to address advanced-stage prostate cancer with improved safety and efficacy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.